Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Post-Traumatic Stress Disorder

    Albuquerque, NM

    Search
    Post-Traumatic Stress Disorder
    Albuquerque, NM
    Show Map
    Map View
    Albuquerque, NM
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      38 Post-Traumatic Stress Disorder Trials near Albuquerque, NM

      Power is an online platform that helps thousands of Post-Traumatic Stress Disorder patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      MDMA Assisted Therapy for PTSD and Opioid Use Disorder

      Albuquerque, New Mexico
      This is an open-label study of the use of MDMA Assisted Therapy for postpartum people with co-occurring Post Traumatic Stress Disorder (PTSD) and Opioid Use Disorder (OUD). The study protocol has been adapted from the Phase 3 studies sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) for PTSD. Due to the high rate of concurrence of PTSD and OUD, people with OUD may experience great benefit from the treatment of their PTSD with MDMA-assisted therapy based on the phase 2 and 3 studies for PTSD. Use of MDMA-assisted therapy in this population has the potential to be of benefit for their OUD and maternal- infant attachment. This study will serve to explore the feasibility and safety of offering MDMA-assisted therapy for treatment of PTSD in postpartum people with opioid use disorder. The CAPs 5 (PTSD) is the primary outcome, the Timeline Follow-Back (TLFB) for opioid use is the secondary outcome and other assessments of opioid use disorder, effects on maternal-infant attachment, social connectedness and other mental health outcomes are exploratory. The study will be conducted at the University of New Mexico Health Sciences Center located in Albuquerque New Mexico. In addition to northern New Mexico being an epicenter of the current opioid use disorder epidemic in the United States there is a long-standing history of multigenerational use of illicit opioids in many communities of northern New Mexico. There are high rates of opioid use disorder on pregnancy and accompanying Neonatal Opioid Use Withdrawal Syndrome (NOWS) in Albuquerque, Santa Fe, and surrounding communities.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorder, Bipolar, Arrhythmia, Others
      Must Be Taking:Methadone, Buprenorphine

      15 Participants Needed

      Brain Stimulation for PTSD

      Albuquerque, New Mexico
      MAGNETS is a prospective, randomized, parallel-design, sham-controlled clinical trial of accelerated, functional magnetic resonance imaging (fMRI)-guided intermittent theta burst stimulation (iTBS) to the right dorsolateral prefrontal cortex (dlPFC) for chronic symptoms of posttraumatic stress disorder (PTSD) in a comorbid Veteran population.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Neurological Disease, Seizures, Psychotic Disorder, Substance Dependence, Others
      Must Be Taking:Psychotropic Medications

      64 Participants Needed

      Quetiapine for Post-Concussion Syndrome

      Albuquerque, New Mexico
      A two site, 2-arm, Phase III randomized pragmatic clinical trial evaluating the effectiveness of quetiapine monotherapy in comparison to Treatment As Usual (TAU) medication management for symptoms experienced by veterans receiving rehabilitation therapy for mild traumatic brain injury (mTBI) and comorbid symptoms of posttraumatic stress disorder (PTSD).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Moderate TBI, Schizophrenia, Bipolar, Others
      Must Be Taking:CNS Active Psychotropics

      146 Participants Needed

      Parenting-STAIR Therapy for Parent-Child Relationship

      El Paso, Texas
      The goal of this study is to assess Parenting STAIR Modular (PSTAIR-M), a promising and innovative intervention for military-connected mothers (MCM) who have experienced trauma and their young children (ages 2-10). PSTAIR-M aims to help mothers manage the strong feelings that sometimes happen after experiencing something scary or stressful, as well as to better connect with their children and manage their behavior effectively. The main questions the study aims to answer are: 1) Does PSTAIR-M reduce maternal PTSD and/or depression symptoms?, and 2) Does PSTAIR-M improve parental functioning? Researchers will compare PSTAIR-M to treatment as usual (TAU) - other EBTs offered at participating study sites - to determine if PSTAIR-M is more effective in improving mental health and parenting. Participants will: 1) attend 12-16 weekly, 1-hour online treatment sessions with their assigned clinicians, 2) complete three 1-hour online assessments administered by research staff, 3) engage with their child in three 15-30-minute online, observed play sessions, and 4) have assessments audio and video recorded.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Suicide Risk, Psychotic Symptoms, Communication Disability, Others

      120 Participants Needed

      Ketamine for Orthopedic Surgery Patients

      Lubbock, Texas
      The goal of this clinical trial is to learn if ketamine, given during surgery, can help improve recovery for adults with serious orthopedic trauma. The study will test whether ketamine reduces pain, lowers the need for opioids, and improves mental health outcomes like depression and post-traumatic stress disorder (PTSD). The main questions it aims to answer are: Does ketamine reduce pain after surgery compared to standard anesthesia? Does ketamine reduce the amount of opioids patients need for pain control? Does ketamine improve symptoms of depression and PTSD after orthopedic trauma? Researchers will compare patients who receive ketamine during surgery with those who receive standard anesthesia without ketamine to see if ketamine helps improve both physical and psychological recovery. Participants will: Be randomly assigned to receive either a single dose of ketamine or standard anesthesia during surgery. Report their pain using a simple pain scale (Visual Analog Scale, VAS). Complete short surveys about mood and mental health (PHQ-9 for depression and PCL-5 for PTSD) at several time points after surgery. Allow the research team to review their electronic medical records to measure opioid prescriptions during recovery. Attend follow-up visits in clinic or by secure telehealth (e.g., Zoom) at 1-7 days, 2-3 weeks, 6 weeks, 3 months, and 6 months after surgery
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Severe Psychiatric, Dementia, Glaucoma, Others
      Must Not Be Taking:Ketamine

      90 Participants Needed

      Inhaled Cannabis for PTSD

      Cave Creek, Arizona
      The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Major Depressive Disorder, Others
      Must Not Be Taking:Antiarrhythmics, Opiates, Methamphetamine, Others

      320 Participants Needed

      Service Dogs + Prolonged Exposure Therapy for PTSD

      Tucson, Arizona
      This study investigates the impact of Service Dog partnership on the effectiveness of Prolonged Exposure Therapy. We will learn whether Service Dog partnership in combination with Prolonged Exposure Therapy treatment can help Veterans with PTSD.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Current Service Dog, Current Therapy

      216 Participants Needed

      Service Dogs for PTSD

      Tucson, Arizona
      Posttraumatic stress disorder (PTSD) among military Veterans is a critical public health concern. Veteran suicide rates exceed those of the general population, with the disorder creating a mental health challenge that is costly and debilitating. The majority of Veterans with PTSD also have comorbid mental health diagnoses, such as generalized anxiety disorder, substance abuse disorder, and major depression. The treatment of Veteran PTSD and comorbid disorders represents an important therapeutic and rehabilitation problem. The disorder is complex and difficult to treat, with high treatment dropout and nonresponse rates spurring some Veterans to seek complementary integrative health strategies. One promising complementary strategy is the provision of a trained service dog. Initial evidence across multiple research groups highlights service dogs as a promising complement to evidence-based practices that can offer short-term improvements. However, the long-term effectiveness, mechanisms of action, and moderators of efficacy remain largely unknown. Thus, the overarching objective of this proposal is to understand how, why, and for whom PTSD service dogs are most effective. To address this objective, the present project will assess the longitudinal efficacy and dose-response curve of service dogs for Veteran PTSD symptomology and psychosocial functioning. The research design will consist of a two-arm, randomized clinical trial (RCT) with longitudinal assessments over a period of 15 months. Results are expected to elucidate the clinical impact of service dogs for military Veterans with PTSD, as well as the biobehavioral mechanisms of action and characteristics that moderate efficacy. These outcomes will support the long-term goal of accelerating complementary and integrative health interventions, through optimized and evidence-based service dog interventions. As such, this project will further advance the scientific understanding of human-animal interactions for psychosocial health.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Generalized Anxiety, Substance Abuse, Major Depression, Others

      150 Participants Needed

      MPACT Intervention for Methadone Treatment

      Tucson, Arizona
      Examine the preliminary effect of the MPACT intervention on methadone treatment retention, in treatment overdose and patient trauma symptoms. The study will also explore the relationship between staff trauma symptoms and MPACT implementation.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Must Be Taking:Methadone

      102 Participants Needed

      Online Parenting Program for Forcibly Displaced Families

      Tempe, Arizona
      This Randomized Controlled Trial will test the effectiveness of the Parenting in the Moment (PIM) online parenting program for parents with experiences of forced displacement. The primary objective of this study is to conduct a summative (impact) evaluation of the PIM online parenting program as an in-home parent, skill-based program for parents of school-aged children, using a randomized controlled trial research design with community partnerships that inform the research throughout. The longer-term objectives are to build the evidence-base for in-home parent skill-based programs with strong empirical support (i.e., eligible for listing on the Families First Clearinghouse) and increase access to parenting programs for forcibly displaced families thereby improving child safety and wellbeing and strengthening their public health support. 720 families will be recruited with forced migration backgrounds and within 10 years of arrival in the USA; 360 families will be assigned to the PIMonline program and 360 to a family resource list only, wait-list control group. Families will be recruited using stratified random sampling within the four PIM language groups: English, Spanish, Arabic, French. Within each language, half the families will be assigned to the PIMonline intervention program and the other half will be assigned to receiving a Family Resource List with access to the PIMonline program once the study ends. One parent and one child per eligible family may participate. Data collection with participating families will take place at baseline (T1), 4-months after baseline (T2) and finally, 16 months after baseline (T3). Data collection includes caregiver online surveys, caregiver and child Zoom recorded Family Interaction Task conversations and interviewer administered child surveys for children aged 8-12 at each time point. Standardized, reliable and valid measures in the four languages will be used to assess change in outcomes through the surveys. Longitudinal growth curve analysis will be used to test PIM intervention effects. Our extensive dissemination plan involves nationwide community partners in child welfare and services to forcibly displaced families.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Prisoners, Impaired Decision-making, Active Psychosis, Others

      720 Participants Needed

      Cognitive Processing Therapy for PTSD

      Phoenix, Arizona
      Recent estimates suggest that over 610,000 US Veterans treated by the Veterans Health Administration (VHA) suffer from PTSD, a disorder that can be chronic and debilitating. The heterogeneity of the 20 symptoms of PTSD; comorbidity with disorders such as depression, panic, and substance use; high rates of lingering effects of physical injury; and suicidality all contribute to complex clinical presentations and can exact a significant toll on functioning, quality of life, and well-being even decades after exposure to the traumatic event. Perhaps spurred by the President's New Freedom Commission on Mental Health, psychosocial rehabilitation has shifted from the periphery in mental health recovery models to a more primary focus in clinical settings, including recommendations for use of psychosocial rehabilitation techniques in trauma-focused mental health care. Support for the efficacy of psychosocial rehabilitation techniques in PTSD recovery programs has burgeoned in recent years and data supporting psychological treatments for PTSD has increased exponentially, yet the two approaches to recovery have largely remained independent. Cognitive Processing Therapy (CPT), the evidence-based psychotherapy (EBP) for PTSD most frequently delivered within VHA, yields large magnitude reductions in primary PTSD outcomes. Corresponding gains in occupational, social, leisure, and sexual functioning, and in health-related concerns have also been demonstrated. Despite CPT's effectiveness, there is room for improvement in overall outcomes and patient engagement. Further, improvements in functioning and quality of life are more modest than those observed in PTSD and associated mental health symptoms. Prior work suggests that unaddressed difficulties in functioning contribute to premature dropout from EBPs for PTSD among Veterans. Directly targeting impairments associated with psychosocial functioning has the potential to substantially increase the scope of recovery beyond the core symptoms of PTSD and facilitate greater patient engagement, resulting in more Veterans benefitting from CPT. Modifying the CPT protocol to personalize the intervention for the individual patient has resulted in better overall response rates for a wider variety of patient populations suffering from complicated clinical presentations. Case formulation (CF) is a well-established approach to cognitive-behavioral treatment that facilitates a collaborative process between providers and patients to guide the tailoring of treatment to meet idiosyncratic patient needs. Integrating CF strategies into the existing CPT protocol will enable providers to personalize CPT to directly address impairment in functioning as well as provide the latitude to directly intervene with the complex challenges that threaten optimal outcomes within the context of trauma-focused therapy. CF-integrated CPT (CF-CPT) expands and enhances the CPT protocol to facilitate a personalized and flexible approach to treating PTSD that prioritizes the administration of the full dose of CPT while expanding the protocol to directly target important domains of functioning and result in more holistic outcomes. This controlled treatment outcome trial will randomize a national sample of CPT providers (Veteran n = 200; provider n = 50) to either deliver CF-CPT or CPT to compare the relative effectiveness of CF-CPT to CPT in improving primary outcomes, including Veterans' psychosocial functioning, quality of life and well-being over the course of treatment and 3-month follow-up as compared to Veterans who receive standard CPT. Further, Veterans who receive CF-CPT will demonstrate greater reductions in PTSD and depression over the course of treatment and 3-month follow-up than those who receive CPT. This study also seeks to determine the effectiveness of CF-CPT as compared to CPT in improving Veterans' treatment engagement (CF-CPT will demonstrate higher rates of Veteran treatment completion than CPT). This study will valuate CF-CPT's indirect impact on Veterans' psychosocial functioning and PTSD/depression symptomology Change in functioning, quality of life, and well-being \& PTSD and depression will be associated with improvement in the idiosyncratic clinical challenges targeted by the CF. This study will also examine between-group differences across secondary outcomes (e.g. anger, anxiety, health concerns, sleep, numbing/reactivity) and describe the frequency and type of the clinical and rehabilitative needs of the Veterans and the type and duration of divergences (e.g. rehabilitative techniques) made by providers.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Suicidal Ideation, Homicidality, Mania, Psychosis, Serious Substance Abuse, Others

      179 Participants Needed

      RRFT for Substance Use and PTSD in Teens

      Denver, Colorado
      This trial tests a new treatment called Risk Reduction through Family Therapy (RRFT) for teens aged 13-18 who have both substance use problems and PTSD due to past trauma. RRFT combines different therapy methods to treat both issues at the same time, involving the family in the process. The goal is to see if this approach works better and if it can be effectively used in regular outpatient settings. Risk Reduction through Family Therapy (RRFT) is an integrative and exposure-based treatment approach for adolescents with substance use problems and PTSD, developed to address the gap in effective treatments for this population.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:13 - 75

      Key Eligibility Criteria

      Disqualifiers:Pervasive Developmental Disability, Active Psychosis, Others

      212 Participants Needed

      SLS-002 for PTSD

      Phoenix, Arizona
      This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for Post Traumatic Stress Disorder (PTSD) utilizing an adaptive platform trial (APT) design. Intervention D - SLS-002 will assess the safety and efficacy of SLS-002 in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Seizures, Hypertension, Cardiovascular Disease, Others
      Must Not Be Taking:MAOIs, Opioids, Antipsychotics, Others

      200 Participants Needed

      Fluoxetine for PTSD

      Phoenix, Arizona
      This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Intervention A - Fluoxetine will assess the safety and efficacy of fluoxetine in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Must Not Be Taking:Fluoxetine

      200 Participants Needed

      Daridorexant for PTSD

      Phoenix, Arizona
      This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Narcolepsy, Others
      Must Not Be Taking:Daridorexant

      200 Participants Needed

      New Treatments for PTSD

      Phoenix, Arizona
      This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). This master protocol describes the default procedures and analyses for all cohorts; treatment-specific procedures will be described in the Master Protocol cohort-specific appendices. Individual cohorts may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in corresponding intervention-specific clinicaltrials.gov records.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Suicide Risk, Substance Use, Others
      Must Not Be Taking:Psychiatric Medications

      800 Participants Needed

      Methylone for PTSD

      Denver, Colorado
      This is an extension study of participants who previously completed a Transcend-sponsored clinical trial evaluating TSND-201 as a treatment for PTSD. Participants will be followed for up to 52 weeks. During the 52 week period, PTSD symptoms and safety will be assessed monthly. Participants' PTSD symptoms will be assessed at each observational visit and if criteria for Relapse has been met, participants may be eligible to receive a course of TSND-201 treatment.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Non-compliance, Physical Or Psychological Findings

      150 Participants Needed

      Integrated Health Care for Post-Traumatic Stress Disorder

      Phoenix, Arizona
      The goal of this clinical trial is to determine whether which types of integrative care, meaning a combination of psychotherapy and mind-body interventions, lead to the most changes in functioning among Veterans with posttraumatic stress disorder (PTSD). The main aims are: 1. To evaluate the impact of integrative care approaches on functional outcomes among Veterans with PTSD. 2. To examine factors relevant to the implementation of integrated treatments for PTSD from the perspective of patients, providers and administrators in the VA Healthcare System. Participants will: 1. Complete assessments at the beginning of the study and 12- and 24-weeks later. 2. Engage in 12 weeks of integrated care, with the type being randomly assigned.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Active Engagement In Included Approaches, Contraindicating Medical Conditions

      300 Participants Needed

      Therapy Methods for Post-Traumatic Stress Disorder

      Phoenix, Arizona
      Investigators' overall objective is to compare methods of identifying individuals who may be experiencing challenges in Cognitive Processing Therapy (CPT) and compare methods of intervening to optimize treatment retention and outcomes. Investigators' specific aims are: 1. to determine whether the use of CPT skills versus collaboratively considering switching to Present Centered Therapy (PCT) is more effective in improving outcomes for individuals experiencing challenges with CPT. Outcomes include post-traumatic stress disorder (PTSD) severity \[primary\], depression, functioning, and treatment retention; 2. to compare two approaches to identifying individuals in CPT in need of additional support during treatment; 3. to study the barriers and facilitators of implementing these intervention strategies. Finally, exploratory aims will examine the stability of differences between treatment conditions, compare combinations of interventions tested, and examine moderators of intervention effects.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Cognitive Impairment, Suicidal Intent, Psychotic Symptoms, Others

      280 Participants Needed

      Partner-Assisted Therapy for PTSD

      Phoenix, Arizona
      PTSD occurs in up to 17% of post-9/11 US Service Members and is associated with long-term functional impairment, family problems, unemployment, and suicidality. Trauma-focused therapies (TFTs), such as Prolonged Exposure (PE), result in significant relief for many. Yet, TFTs are not equally effective for everyone. An important minority (\~40%) will retain their PTSD diagnoses after treatment, and many discontinue treatment prematurely, especially post-9/11 Service Members. TFTs are also more effective in addressing symptoms than psychosocial functioning. More work is needed to improve the consistency and potency of TFTs. Partnering with significant others may provide a powerful method for helping individuals get more out of their PTSD treatment. Observational research shows that relationship factors can help patients initiate, stay in, and experience greater benefit from PTSD treatment. Veterans that were surveyed experienced greater treatment gains when they shared more about their treatment with loved ones and when loved ones accommodated less for PTSD symptoms. Despite the promise of partner-involved interventions, there is no couples approach to PTSD treatment that has demonstrated superior outcomes to individual-only treatment models (i.e., TFTs). To address this gap, the investigators have completed a series of partner-assisted PTSD treatment studies, leading up the current proposal (Partnered PE, PPE). The investigators found that treatment completion rates were better than routine clinical care, and the treatment led to large improvements in participants' functioning, PTSD symptoms, and romantic functioning. For this proposed study, the primary objective is to conduct a randomized controlled trial (Research Level 3; larger-scale clinical trial) to test the superiority of PPE to standard PE among post 9/11 Veterans. The investigator's primary hypothesis is that PPE will lead to greater improvements in psychosocial functioning than standard PE. Secondary and tertiary aims examine posttreatment clinical outcomes (PTSD, depression) and intimate partner outcomes (relationship functioning, distress, caregiver burden, and psychosocial functioning), as well as examine strategies for PPE implementation. In exploratory aims, the investigators will examine the stability of group differences, treatment completion rates, the role military sexual trauma history, and treatment mechanisms.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Imminent Suicidality, Mania, Psychosis, Others

      420 Participants Needed

      Why Other Patients Applied

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Post-Traumatic Stress Disorder Trial

      NightWare for Post-Traumatic Stress Disorder

      Denver, Colorado
      The purpose of this study is to determine whether NightWare therapeutic intervention improves biomarkers of vascular and renal function in premenopausal women with PTSD-related nightmares, and examine whether these improvements restore them to levels observed in age-matched women without PTSD.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:22 - 40
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Hypertension, Cancer, Others
      Must Not Be Taking:Antihypertensives, Lipid-lowering, Insulin, Others

      36 Participants Needed

      Mindfulness Training for PTSD

      Phoenix, Arizona
      This trial compares mindfulness meditation and problem-solving skills classes for Veterans with anxiety, depression, or PTSD. It aims to see which method better reduces symptoms and improves overall functioning in 300 Veterans across various locations. Mindfulness-based stress reduction (MBSR) has been studied extensively and shown to improve PTSD symptoms, depression, and overall well-being in veterans.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Cognitive Impairment, Recent Suicide Attempt, Others

      300 Participants Needed

      Antidepressants + Therapy for PTSD

      Aurora, Colorado
      Individuals with PTSD are more likely to engage in unhealthy behaviors such as tobacco use, drug use, alcohol misuse, and have high rates of morbidity/mortality. PTSD negatively impacts marriages, educational attainment, and occupational functioning. Some patients with PTSD can be successfully referred to specialty mental health clinics, but most patients with PTSD cannot engage in specialty care because of geographical, financial and cultural barriers and must be treated in primary care. However, policy makers do not know the best way to treat PTSD in primary care clinics, especially for patients who do not respond to the initial treatment choice. There are effective treatments for PTSD that are feasible to deliver in primary care. These treatments include commonly prescribed antidepressants and brief exposure-based therapies. However, because there are no head-to-head comparisons between pharmacotherapy and psychotherapy in primary care settings, primary care providers do not know which treatments to recommend to their patients. In addition, despite high treatment non-response rates, very few studies have examined which treatment should be recommend next when patients do not respond well to the first, and no such studies have been conducted in primary care settings. This trial will be conducted in Federally Qualified Health Centers and VA Medical Centers, where the prevalence of both past trauma exposure and PTSD are particularly high. The investigators will enroll 700 primary care patients. The investigators propose to 1) compare outcomes among patients randomized to initially receive pharmacotherapy or brief psychotherapy, 2) compare outcomes among patients randomized to treatment sequences (i.e., switching and augmenting) for patients not responding to the initial treatment and 3) examine variation in treatment outcomes among different subgroups of patients. Telephone and web surveys will be used to assessed outcomes important to patients, like self-reported symptom burden, side-effects, health related quality of life, and recovery outcomes, at baseline, 4 and 8 months. Results will help patients and primary care providers choose which treatment to try first and which treatment to try second if the first is not effective.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      700 Participants Needed

      Probiotics for PTSD

      Denver, Colorado
      This trial investigates using a beneficial bacteria called Lactobacillus rhamnosus GG (LGG) to help U.S. military Veterans with PTSD who do not respond well to traditional treatments. The probiotic aims to reduce inflammation in the body and brain, which is a common issue in PTSD. By balancing gut bacteria, it may improve PTSD symptoms and overall stress response. Lactobacillus rhamnosus GG (LGG) has shown several beneficial effects, including improved insulin sensitivity and anti-inflammatory properties.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Alcohol, Substance Abuse, Bipolar, Others
      Must Not Be Taking:Antifungals, Antivirals, Antiparasitics, Others

      150 Participants Needed

      Whole Health Intervention for PTSD

      Aurora, Colorado
      This trial tests Omnis Salutis, a program for recent veterans of the Afghanistan and Iraq conflicts. The program helps veterans set and share their health goals with doctors and support systems to improve their well-being.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Affective Psychoses, Others

      238 Participants Needed

      Project Safe Guard-Trauma for PTSD

      Aurora, Colorado
      The goal of this randomized controlled trial is to determine if a counseling intervention, Project Safe Guard-Trauma (PSG-T), increases secure firearm storage practices in adults who screen positive for posttraumatic stress disorder (PTSD). The main questions this study aims to answer are: * Does PSG-T lead to more secure firearm storage practices? * Does PSG-T increase knowledge about the link between firearm storage practices and suicide risk? * Does PSG-T increase intentions to store firearms securely? Researchers will compare PSG-T to a control, Project Safe Guard (PSG), which is a counseling intervention that does not focus on the potential influence of PTSD symptoms on firearm storage practices. This will help to determine if PSG-T works better than PSG to increase secure firearm storage in adults with elevated PTSD symptoms. Participants will: * Complete a baseline survey * Receive the counseling intervention * Complete a survey immediately after the intervention and at 1-, 3-, and 6-months following the intervention
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Active Psychosis, Acute Mania, Others

      168 Participants Needed

      NightWare for PTSD

      Aurora, Colorado
      The purpose of this study is to learn more about the effectiveness of a prescription wrist-wearable device called NightWare (NW) on improving sleep in Veterans with nightmares related to posttraumatic stress disorder (PTSD). The investigators also want to learn whether it improves cardiovascular health among this population.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:22 - 88

      Key Eligibility Criteria

      Disqualifiers:Unstable Medical Condition, Pregnancy, Substance Abuse, Others
      Must Not Be Taking:Insulin, Sulfonylureas

      125 Participants Needed

      PATH Program for NICU Parent Mental Health

      Aurora, Colorado
      The objective of this study is to develop and pilot test a telehealth-based mental health screening and engagement program that supports parents as their infants transition home from the NICU. The program will use a stepped-care approach to screen parents for depression, anxiety, and PTSD; provide a brief behavioral intervention to those who screen as having at least a low risk of these conditions; and provide a warm hand-off to community mental health services for those at medium to high risk.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Non-English/Spanish Speakers, Others

      72 Participants Needed

      MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

      Boulder, Colorado
      The purpose of this study is to assess the safety and efficacy of MDMA-Assisted Therapy on Health Care Workers suffering from symptoms of Post-Traumatic Stress due to their work on the frontline of the COVID Pandemic.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorder, Bipolar I, Others
      Must Not Be Taking:QT Prolonging Drugs

      30 Participants Needed

      Vegetable Drinks for Post-Traumatic Stress Disorder

      Fort Collins, Colorado
      The gut microbiome has been shown to impact various facets of human health, including mental health. Studies have shown that populations with more agrarian lifestyles tend to have fewer chronic diseases and mental health issues than industrialized populations. A possible factor in these differences is the loss of co-evolved gut microbial taxa that has occurred with Westernization. This hypothesis, termed "Old Friends Hypothesis" suggests that the loss of certain gut microbes leads to immune dysregulation and increased chronic inflammation that contributes to development of cancers, cardiometabolic diseases and even neuroinflammation that can lead to negative behavioral and mental health outcomes. Other studies have shown that increasing the intake of plant foods may help increase diversity of the microbes in the gut and that this increased diversity could lead to better health outcomes in humans. The investigators propose to evaluate daily consumption of a drink consisting of a high diversity of plants (30 plant species) for four weeks on the diversity of the gut microbiome, biological signatures of inflammation, quality of life, sleep quality, and PTSD symptoms among persons with a diagnosis of PTSD. The investigators hypothesize that four weeks of daily consumption of this high plant diversity beverage (30 plant species) will increase gut microbiome ɑ-diversity, reduce markers of systemic inflammation, and improve PTSD symptom severity relative to daily consumption of a beverage containing only three plant species.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Vegan, Gastrointestinal Diseases, Cancer, Others
      Must Not Be Taking:Antibiotics

      40 Participants Needed

      12

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Post-Traumatic Stress Disorder clinical trials in Albuquerque, NM pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Post-Traumatic Stress Disorder clinical trials in Albuquerque, NM work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Post-Traumatic Stress Disorder trials in Albuquerque, NM 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Albuquerque, NM for Post-Traumatic Stress Disorder is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Albuquerque, NM several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Post-Traumatic Stress Disorder medical study in Albuquerque, NM?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Post-Traumatic Stress Disorder clinical trials in Albuquerque, NM?

      Most recently, we added MDMA-Assisted Therapy for Post-Traumatic Stress Disorder, Inhaled Cannabis for PTSD and Integrated Health Care for Post-Traumatic Stress Disorder to the Power online platform.

      What is the new treatment for PTSD?

      The two headline “new” approaches are MDMA-assisted psychotherapy—which has shown large symptom reductions in Phase-3 trials and could gain FDA approval soon—and the stellate ganglion block, an ultrasound-guided neck injection that can rapidly calm the nervous system and is already offered off-label by some pain specialists. Both are considered add-ons rather than replacements for proven trauma-focused talk therapies, and access currently means enrolling in a clinical trial for MDMA or seeing an experienced clinician for an SGB after discussing possible benefits, side-effects, and costs. If you’re interested, talk with a PTSD-trained mental-health professional to see whether one of these emerging treatments fits your situation.

      What are the 7 symptoms of PTSD?

      Clinicians group PTSD signs into four clusters, but popular summaries often point to seven tell-tale symptoms: intrusive memories or flashbacks, trauma-related nightmares, avoiding reminders, ongoing negative mood or beliefs, constant jumpiness/hyper-alertness, sudden irritability or anger, and trouble sleeping or concentrating. If several of these have lasted more than a month and are disrupting daily life, it’s time to talk with a mental-health professional because effective therapies and medications are available.

      What is the difference between PTSD and clinical PTSD?

      “Clinical PTSD” is not a formal medical label; most people use it to describe either (a) a full, doctor-confirmed PTSD diagnosis (meeting all four symptom clusters of intrusion, avoidance, negative mood/thoughts, and hyper-arousal) rather than a few stray symptoms, or (b) Complex PTSD, a newer ICD-11 diagnosis that includes all the usual PTSD features plus persistent problems with emotion control, negative self-view, and relationships after prolonged or repeated trauma. In short, standard PTSD focuses on how a single or short-lived traumatic event is re-experienced, whereas “clinical/complex” PTSD implies either full diagnostic severity or an added layer of long-term self-and-relationship difficulties—something a qualified mental-health professional can sort out and treat with trauma-focused therapy and, when needed, medication.

      Does complex PTSD ever go away?

      Complex PTSD can and often does get much better—many people reach full remission or only occasional, manageable flare-ups once they’ve had consistent, trauma-focused treatment (such as EMDR, TF-CBT, or a phase-based approach that first builds safety skills and then processes the trauma). How long that takes varies; factors like the length of the original abuse, other mental-health conditions, and access to supportive relationships and specialized care influence recovery, which is why some people need longer-term therapy or periodic “tune-ups.” In short, the condition isn’t necessarily lifelong, but viewing it as a journey—with professional help, skills practice, and a strong support network—gives the best odds of lasting relief.

      Why is EMDR controversial?

      Controversy arises from three fronts: first, although many studies now show EMDR can reduce post-traumatic stress as well as traditional exposure therapies, earlier weak studies and some mixed results planted doubt. Second, research shows the eye movements themselves may add little beyond standard exposure, so experts argue over the true mechanism and whether the name oversells a simple idea. Third, professional bodies only “conditionally” recommend EMDR and warn that brief weekend trainings can produce under-qualified providers, leading some clinicians to view it as over-marketed. Understanding these evidence, mechanism, and training debates explains why opinions on EMDR still differ.

      Does PTSD count as a disability?

      Yes. PTSD is legally treated as a disability whenever its symptoms are documented to substantially limit major life activities: Social Security can grant cash benefits, the VA can award a disability rating for service-connected stress, and the ADA requires employers to offer reasonable job accommodations. Collect medical records that show both a formal PTSD diagnosis and how it disrupts work, school, or daily tasks—the same principle applies in most other countries’ disability systems.

      How to heal from trauma without therapy?

      Begin by checking safety: if you’re having thoughts of self-harm, losing touch with reality, or using substances to cope, call a crisis line (e.g., 988 in the U.S.) or seek professional help. Otherwise, think of recovery in three daily practices—steady your body (slow breathing, walking, yoga), give the story gentle airtime (15-minute journaling or a free app like PTSD Coach), and reconnect with supportive people and purposeful activities—while tracking sleep, mood, and triggers each week to see progress. If symptoms stay the same or worsen after a couple of months of consistent effort, that’s your signal to add a trained therapist, group program, or tele-health option.

      What diagnosis is close to PTSD?

      The diagnosis most often mistaken for PTSD is Acute Stress Disorder—symptoms can look identical, but they start within days of the trauma and fade within a month; if they last longer, the label changes to PTSD. Clinicians also consider Complex PTSD (a longer-term form after chronic abuse), Adjustment Disorder (stress-triggered distress without flashbacks), and common anxiety or depression disorders that share sleep, mood or panic problems but are not tied to a specific traumatic memory. A mental-health professional sorts these out by asking about the kind of event that happened, how long symptoms have lasted, and whether true “re-experiencing” (flashbacks or nightmares of the trauma) is present.

      Why is PTSD so hard to treat?

      PTSD is tough to heal because severe stress literally rewires the brain’s alarm and memory centres, every person’s trauma history is different, and the core symptoms (avoidance, distrust, numbness) make it hard to start or stay in treatment. Recovery therefore usually requires a personalised mix of approaches—such as trauma-focused therapy, medication, and skills for sleep and safety—and patience while you and your clinician adjust the plan. The good news is that most people do improve, and newer tools like EMDR, virtual-reality exposure, ketamine or MDMA-assisted therapy are widening the options when first-line methods fall short.

      Does Stellate ganglion block work for PTSD?

      A stellate ganglion block can quiet the “fight-or-flight” nerves, and small studies—mainly in military populations—show it can lessen PTSD symptoms in roughly half of patients for a month or two; other trials have found no clear benefit, so results are mixed. Because evidence is still limited and short-term, specialists usually offer SGB only as an adjunct to proven treatments (therapy, medications) after weighing its brief relief against the need for repeat injections and the procedure’s small but real risks (infection, hoarse voice, temporary eyelid droop). Discussing it with a trauma-focused mental-health provider and an experienced pain or anesthesia physician can help decide if this experimental option makes sense in your overall care plan.

      Popular Searches

      By Condition

      Depression Clinical Trials in New Mexico

      Anxiety Clinical Trials in New Mexico

      Schizophrenia Clinical Trials in New Mexico

      ADHD Clinical Trials in New Mexico

      Bipolar Disorder Clinical Trials in New Mexico

      Multiple Sclerosis Clinical Trials in New Mexico

      Autism Clinical Trials in New Mexico

      Treatment Resistant Depression Clinical Trials in New Mexico

      Borderline Personality Disorder Clinical Trials in New Mexico

      Social Anxiety Disorder Clinical Trials in New Mexico

      Parkinson's Disease Clinical Trials in New Mexico

      Alzheimer's Disease Clinical Trials in New Mexico

      By Location

      Clinical Trials near Albuquerque, NM

      Clinical Trials near Santa Fe, NM

      Clinical Trials near Las Cruces, NM

      Clinical Trials near Farmington, NM

      Clinical Trials near Rio Rancho, NM

      Clinical Trials near Gallup, NM

      Clinical Trials near Shiprock, NM

      Clinical Trials near Alburquerque, NM

      Clinical Trials near Los Alamos, NM

      Clinical Trials near Sante Fe, NM

      Clinical Trials near Alamogordo, NM

      Clinical Trials near Taos, NM

      Other People Viewed

      By Subject

      17 Post-Traumatic Stress Disorder Trials near Glendale, AZ

      22 Post-Traumatic Stress Disorder Trials near Houston, TX

      184 Post-Traumatic Stress Disorder Trials near Boston, MA

      26 Post-Traumatic Stress Disorder Trials near Raleigh, NC

      34 Post-Traumatic Stress Disorder Trials near Austin, TX

      29 Post-Traumatic Stress Disorder Trials near New York, NY

      30 Post-Traumatic Stress Disorder Trials near Chicago, IL

      152 Post-Traumatic Stress Disorder Trials near San Antonio, TX

      26 Tinnitus Trials near Miami, FL

      Top Post-Traumatic Stress Disorder Clinical Trials near Baltimore, MD

      Top Post Traumatic Stress Clinical Trials

      Top Colorectal Cancer Clinical Trials near Albuquerque, NM

      By Trial

      Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder

      Quetiapine for Post-Concussion Syndrome

      Web-Based Therapy for PTSD

      CPT + rTMS for PTSD

      Written Exposure Therapy for PTSD in Veterans with Substance Use Disorders

      Behavior Therapy for Adjustment Disorder

      NightWare for Post-Traumatic Stress Disorder

      NDR vs. NightWare Wristband for Trauma-Related Nightmares

      Wellness Program for Trauma

      ACT Intervention for Post-Surgery Back Pain

      Healthy Lifestyle Intervention for Emotional Distress During Pregnancy

      Tai Chi + Wellness for Gulf War Syndrome

      Related Searches

      Top Post-traumatic-stress-disorder Clinical Trials near New York, NY

      Top Post-traumatic-stress-disorder Clinical Trials near Ventura, CA

      Top Prostatitis Clinical Trials

      Top Post-traumatic-stress-disorder Clinical Trials near Austin, TX

      Top Post-traumatic-stress-disorder Clinical Trials near San Antonio, TX

      Top Post-traumatic-stress-disorder Clinical Trials near Los Angeles, CA

      Top Post-traumatic-stress-disorder Clinical Trials near Baltimore, MD

      Transcutaneous Spinal Stimulation for Spina Bifida

      Fear Conditioning for Anxiety and Post-Traumatic Stress Disorder

      Therapy Methods for Post-Traumatic Stress Disorder

      CRD3874 for AML

      SAR442970 for Ulcerative Colitis